Cendakimab

(Synonyms: RPC 4046; ABT 308; CC-93538)
1 Cited Publications
Customer Review

Based on 1 publication(s) in Google Scholar

Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis).

For research use only. We do not sell to patients.

  • Purity: 99.96%
  • CAS No.: 2151032-62-9
  • Molecular Weight:146.44 kDa
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs

Publications Citing Use of MedChemExpress (MCE) Cendakimab

More
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00